Evidence map›Paper›PMID 42839074›Full record

ArticleLeukemia2026

KT-253, a highly potent and selective MDM2 protein degrader, eliminates malignant myelofibrosis stem/progenitor cells.

Min Lu, Lijuan Xia, Yogesh Chutake, Joyoti Dey, Ronald Hoffman

Abstract read
PubMed Publisher
In one paragraph

Article in Leukemia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Min LuDivision of Hematology/Oncology, Mount Sinai Tisch Cancer Center and Department of Medicine, Myeloproliferative Neoplasm-Research Consortium, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA. min.lu@mssm.edu.ORCID http://orcid.org/0000-0002-4191-4787
Lijuan XiaDivision of Hematology/Oncology, Mount Sinai Tisch Cancer Center and Department of Medicine, Myeloproliferative Neoplasm-Research Consortium, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
Yogesh ChutakeKymera Therapeutics Inc., 500 North Beacon St., Watertown, MA, 02472, USA.
Joyoti DeyKymera Therapeutics Inc., 500 North Beacon St., Watertown, MA, 02472, USA.
Ronald HoffmanDivision of Hematology/Oncology, Mount Sinai Tisch Cancer Center and Department of Medicine, Myeloproliferative Neoplasm-Research Consortium, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA. ronald.hoffman@mssm.edu.ORCID http://orcid.org/0000-0001-6564-6732

Funding

Tissue BankP01CA108671 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI Ross L Levine · 2006 to 2026
$82.0M
U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) P01 CA108671
6 · The paper itself

Abstract

Approximately 96% of myelofibrosis (MF) patients express wild-type (WT) p53. MF hematopoietic stem/progenitor cells (HSPCs) overexpress MDM2 that degrades WTp53, thereby supporting MF HSPC survival. Although MDM2 small-molecule inhibitors (SMIs) are clinically effective, their benefit is compromised by an inability to sufficiently deplete MF HSPCs. KT-253 degrades MDM2 and overcomes the p53-dependent feedback loop that restores MDM2 levels observed with the use of MDM2 SMIs such as AMG-232. We evaluated the effects of KT-253 using MPN cell lines, primary MF CD34

Identifiers

PMID42839074

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.